Significance of Interleukin Polymorphisms Multiple Sclerosis Associations

Multiple sclerosis represents a debilitating neuroinflammatory condition characterized by focal demyelination and progressive neuroaxonal degeneration. Furthermore, complex genetic factors profoundly influence disease susceptibility, progression rates, and clinical outcomes. Recent investigations into interleukin polymorphisms multiple sclerosis linkages reveal how genetic variations in inflammatory cascades modulate clinical trajectories. Interleukins act as crucial immunomodulatory proteins governing leukocyte activation, neurovascular permeability, and glial recruitment within the central nervous system. In a recent case-control study involving 271 Egyptian individuals, researchers investigated specific polymorphisms within the interleukin-18 and interleukin-21 genes. The cohort comprised 131 patients with multiple sclerosis alongside 140 healthy, unrelated controls. Among the diagnosed patients, 99 presented with relapsing-remitting multiple sclerosis, whereas 32 exhibited progressive disease subtypes. The investigators genotyped the IL-18-137G/C (rs187238) and IL-21-1472G/T (rs2055979) single nucleotide polymorphisms using polymerase chain reaction methodologies. Consequently, statistical evaluations confirmed significant differences in genotypic distributions between affected patients and healthy controls. Moreover, these findings highlight how inherited variations regulate individual inflammatory intensity. Therefore, dissecting these cytokine variants provides deeper insight into disease heterogeneity, enabling clinicians to appreciate the biological underpinnings governing varied patient presentations. Accordingly, understanding these immunogenetic markers aids in deciphering complex neurological phenotypes.

Pathophysiological Role of Interleukin-18 in Demyelinating Disease

Interleukin-18 functions as a potent proinflammatory cytokine within the broader interleukin-1 cytokine family. Specifically, this cytokine stimulates interferon-gamma synthesis from natural killer cells and T helper 1 lymphocytes. In autoimmune neuroinflammation, excessive interleukin-18 activity promotes blood-brain barrier breakdown and facilitates immune cell infiltration into neural tissue. Furthermore, activated resident microglia and infiltrating peripheral macrophages actively release interleukin-18 within active demyelinating lesions. In the clinical cohort, the IL-18-137G/C polymorphism displayed a strong association with multiple sclerosis risk. Specifically, both the heterozygous GC genotype and the C allele correlated with heightened disease susceptibility. Moreover, individuals carrying GC or CC genotypes demonstrated an elevated vulnerability to progressive multiple sclerosis phenotypes. Regression analyses further affirmed that this genetic variant independently predicted increased physical disability measured by the Expanded Disability Status Scale. Consequently, this single nucleotide polymorphism appears to enhance transcriptional activity, provoking sustained neuroinflammatory damage. As a result, excessive cytokine production exacerbates oligodendrocyte cytotoxicity and impairs endogenous remyelination capacity. Ultimately, profiling interleukin-18 variants helps clinicians identify patients prone to severe neuroinflammatory cascades. Therefore, these findings support the critical role of interleukin-18 in escalating long-term central nervous system damage.

Protective Potential of the IL-21-1472G/T Gene Polymorphism

While interleukin-18 primarily drives tissue damage, interleukin-21 plays multifaceted immunoregulatory roles across diverse lymphocyte populations. Interleukin-21 modulates B-cell proliferation, plasma cell differentiation, and follicular helper T-cell survival. Interestingly, the investigation demonstrated that the IL-21-1472G/T polymorphism confers meaningful protection against disease progression. Egyptian multiple sclerosis patients carrying the TT genotype or the T allele displayed a significantly reduced risk of developing progressive forms compared to relapsing-remitting cases. However, researchers observed that this genetic variation was not associated with short-term disability progression or overall clinical severity. Nevertheless, the reduced incidence of progressive multiple sclerosis among T allele carriers suggests a significant biological buffer against chronic neurodegeneration. Perhaps this allele downregulates aberrant humoral responses or limits follicular helper T-cell activity within tertiary lymphoid structures. Consequently, preserving immune equilibrium within the central nervous system may prevent destructive transitions from relapsing to progressive phenotypes. Therefore, examining interleukin-21 polymorphisms alongside proinflammatory markers provides a comprehensive view of individual immunogenetic resilience. Ultimately, balanced cytokine signaling remains essential for curbing progressive neurological impairment. In addition, these genetic insights illuminate potential targets for future neuroprotective and immunomodulatory interventions.

Clinical Implications for Disease Staging and Disability Monitoring

Accurately predicting long-term neurological disability remains a major diagnostic priority in managing demyelinating disorders. Currently, clinicians evaluate physical impairment through the Expanded Disability Status Scale alongside serial magnetic resonance imaging. However, standard clinical tools frequently fail to anticipate which patients will experience rapid neurological decline. Incorporating genetic data, particularly the IL-18-137G/C variant, could significantly enhance prognostic accuracy during initial patient evaluations. Because this polymorphism independently predicts higher disability metrics, identifying the C allele enables clinicians to recognize high-risk patients earlier in their disease course. Consequently, treating neurologists can implement proactive management strategies, including earlier escalation to high-efficacy disease-modifying therapies. Furthermore, targeted monitoring protocols can track subtle neurological worsening before irreversible axonal destruction occurs. In contrast, recognizing protective alleles like IL-21-1472G/T offers valuable context regarding lower risk for progressive transition. Therefore, integrating genomic profiling with clinical scoring tools establishes a more nuanced framework for patient assessment. Ultimately, personalized prognostic biomarkers empower clinicians to deliver timely, aggressive interventions tailored to individual biological risk profiles. Additionally, risk-stratified surveillance allows neurologists to optimize clinical appointment schedules and tailor rehabilitation support proactively.

Translational Relevance for Indian Healthcare and Future Perspectives

The findings from this Egyptian investigation provide vital biological insights relevant to clinical practice across diverse global populations, including India. Indian clinicians face distinct challenges in diagnosing and managing demyelinating disorders, given the country's vast ethnic diversity and emerging autoimmune disease burden. Although allele frequencies naturally differ across ethnic cohorts, the underlying cytokine mechanisms remain universally significant. Specifically, chronic neuroinflammation driven by interleukin cascades contributes to therapeutic resistance and accelerated axonal degeneration in susceptible individuals. Therefore, validating cytokine polymorphisms across Indian patient cohorts through multicenter genomic registries represents an essential next step. In addition, future therapeutic strategies might directly target interleukin-18 pathways to halt progressive neurodegeneration. Conversely, modulating interleukin-21 signaling could preserve protective regulatory mechanisms. While routine genetic testing is not yet integrated into daily standard protocols, translational neuroimmunology is advancing rapidly. Consequently, bridging genetic research with clinical practice will facilitate personalized therapeutic approaches for multiple sclerosis. Ultimately, investing in targeted biomarker discovery will improve clinical risk assessment and patient outcomes across South Asia. Accordingly, future clinical guidelines may incorporate immunogenetic screening to enhance personalized neurological care across developing nations.

Frequently Asked Questions

How does the IL-18-137G/C polymorphism influence multiple sclerosis risk?

The IL-18-137G/C polymorphism significantly elevates disease risk, as both the heterozygous GC genotype and C allele correlate with heightened multiple sclerosis susceptibility. Furthermore, carriers face an increased likelihood of progressive disease transformation and experience greater disability accumulation as measured by the Expanded Disability Status Scale.

What protective role does the IL-21-1472G/T gene variant provide?

The IL-21-1472G/T single nucleotide polymorphism acts as a protective genetic factor against progressive multiple sclerosis. Specifically, patients carrying the TT genotype or T allele exhibit significantly reduced odds of developing secondary progressive pathology, although this genetic variant does not directly alter overall disease severity or acute progression scores.

Are cytokine genetic tests routinely recommended in daily clinical neurology?

Currently, routine cytokine genotyping is not recommended in standard clinical guidelines for multiple sclerosis diagnosis. Clinicians primarily rely on clinical evaluation, neuroimaging, and cerebrospinal fluid testing. However, ongoing genetic research offers valuable prognostic insights that may soon enhance personalized risk stratification, therapeutic drug selection, and disease monitoring protocols.

Disclaimer: This content is for informational and educational purposes only and should not be considered as medical advice or a substitute for professional clinical judgment. Diagnostic criteria, treatment pathways, and drug choices should be customized based on individualized patient assessment, institutional protocols, and current expert consensus. Refer to the latest local and national guidelines for clinical practice.

References

1. Bakr NM et al. Impact of genetic polymorphisms in the interleukin-18 and interleukin-21 genes on the risk and clinical outcomes of multiple sclerosis. BMC Neurol. 2026 May 25. doi: 10.1186/s12883-026-04869-7. PMID: 42185985.


2. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502-1517.


3. Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015;15(9):545-558.


4. Kunkl M, Frascolla S, Amormino C, Volpe E, Tuosto L. T Helper Cells: The Modulators of Inflammation in Multiple Sclerosis. Cells. 2020;9(2):482.